Non-pegylated liposomal doxorubicin use in the treatment of bilateral breast cancer

Abstract

Breast cancer is the most common cancer between women. It is the most common cancer among residents of USA, Canada, Australia and West Europe. Metastatic breast cancer is an incurable disease. Women with metastatic breast cancer are treated with systemic therapy. In this phase of the disease treatment is palliative and its aim is to prolong and improve the quality of life. Not yet determined the optimal first-line treatment regimen. The selection should take into account the effectiveness and adverse event profile depending on the individual characteristics of patients. The most active biological agents used to treat breast cancer are anthracyclines. The use of anthracyclines is limited by their cardiotoxicity mainly as a consequence of triggering of congestive heart failure. Currently, there is a possibility to re-apply after the introduction of liposomal anthracyclines form of these drugs.
Onkol. Prak. Klin. 2010; supl. A: A40–A42